Kerala Ayurveda Ltd.
| BSE: 530163 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE817B01025 |
| BSE 00:00 | 20 Apr | 98.50 |
0.30 (0.31%) |
OPEN
98.25 |
HIGH
100.65 |
LOW
96.50 |
| NSE 05:30 | 01 Jan | Kerala Ayurveda Ltd |
| OPEN | 98.25 |
| PREVIOUS CLOSE | 98.20 |
| VOLUME | 10465 |
| 52-Week high | 120.90 |
| 52-Week low | 64.00 |
| P/E | 43.39 |
| Mkt Cap.(Rs cr) | 104 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Kerala Ayurveda Ltd. (KERALAAYURVEDA) - Net Profit
Net Profit
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
| Lupin | 798.35 | 8.25 | 1.04 | 3141.33 |
| Glenmark Pharma. | 572.35 | 7.30 | 1.29 | 2140.61 |
| Aurobindo Pharma | 618.50 | 1.35 | 0.22 | 1706.76 |
| Dr Reddy's Labs | 2120.50 | -9.90 | -0.46 | 1384.10 |
| Divi's Lab. | 1193.85 | 9.50 | 0.80 | 1053.27 |
| Cipla | 587.85 | 3.65 | 0.62 | 974.94 |
| Alkem Lab | 1776.00 | -23.70 | -1.32 | 883.16 |
| Torrent Pharma. | 1397.05 | 4.70 | 0.34 | 854.22 |
| Piramal Enterp. | 2571.00 | -30.30 | -1.16 | 776.78 |
| Cadila Health. | 384.80 | -1.85 | -0.48 | 661.90 |
| Biocon | 637.55 | -2.00 | -0.31 | 519.30 |
| Ajanta Pharma | 1366.40 | -16.10 | -1.16 | 499.81 |
| Natco Pharma | 801.40 | 1.55 | 0.19 | 494.80 |
| Alembic Pharma | 501.10 | 0.55 | 0.11 | 430.63 |
| Glaxosmi. Pharma | 2432.90 | 54.65 | 2.30 | 336.78 |
| Pfizer | 2225.65 | 73.10 | 3.40 | 336.78 |
| Sanofi India | 4999.50 | -47.10 | -0.93 | 326.00 |
| Syngene Intl. | 643.95 | -6.20 | -0.95 | 287.30 |
| Apollo Hospitals | 1132.60 | 10.65 | 0.95 | 285.15 |
| Abbott India | 6137.75 | -24.95 | -0.40 | 276.65 |
Quick Links for Kerala Ayurveda:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
